Licensing · GCC · Announced 9 Oct 2026
Genepharm → ADCAN Pharma
Licensing deal between Genepharm (Greece) and ADCAN Pharma (United Arab Emirates), announced 9 Oct 2026.
Parties: Genepharm S.A. (Greece) → ADCAN PHARMA (United Arab Emirates)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- UAE, KSA and wider GCC (per Genepharm COO statement)
- Therapeutic area
- Cardiovascular
- Asset
- Licensing and technology transfer agreement across two therapy areas: Oncology and Cardiology (per ADCAN's official announcement, "double impact" dual-focus partnership)
- Announced
- 9 Oct 2026
Our analysis
Why this matters
The third of ADCAN's five CPHI deals with an official dedicated announcement — and it is the one with the deepest existing regional footprint behind it. Our dataset shows Genepharm with ~218 regional registrations (Jordan 63, Saudi 45, Iraq 32, Kuwait 32, Lebanon 18) — a company already selling across the region, now choosing ADCAN as its UAE manufacturing licensee.
Genepharm's COO Evangelos Anagnostopoulos said it directly: this deal "marks an important step in Genepharm's strategy to strengthen its presence in the UAE and the wider GCC region."
The full analysis is free to read with a work email on this page.